Home >> Healthcare >> Food & Beverage >>

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2015

Published: Aug-2015 | Format: PDF | Global Markets Direct | Number of pages: 119 | Code: MRS - 35119

Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Hospital Acquired Pneumonia (HAP) - Pipeline Review, H2 2015’, provides an overview of the Hospital Acquired Pneumonia (HAP)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hospital Acquired Pneumonia (HAP), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hospital Acquired Pneumonia (HAP) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hospital Acquired Pneumonia (HAP)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Hospital Acquired Pneumonia (HAP) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Hospital Acquired Pneumonia (HAP) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hospital Acquired Pneumonia (HAP) pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hospital Acquired Pneumonia (HAP)
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hospital Acquired Pneumonia (HAP) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Hospital Acquired Pneumonia (HAP) Overview 9
Therapeutics Development 10
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Overview 10
Pipeline Products for Hospital Acquired Pneumonia (HAP) - Comparative Analysis 11
Hospital Acquired Pneumonia (HAP) - Therapeutics under Development by Companies 12
Hospital Acquired Pneumonia (HAP) - Therapeutics under Investigation by Universities/Institutes 14
Hospital Acquired Pneumonia (HAP) - Pipeline Products Glance 15
Late Stage Products 15
Clinical Stage Products 16
Early Stage Products 17
Unknown Stage Products 18
Hospital Acquired Pneumonia (HAP) - Products under Development by Companies 19
Hospital Acquired Pneumonia (HAP) - Products under Investigation by Universities/Institutes 21
Hospital Acquired Pneumonia (HAP) - Companies Involved in Therapeutics Development 22
Achaogen Inc. 22
Adenium Biotech ApS 23
Aridis Pharmaceuticals LLC 24
AstraZeneca Plc 25
Cardeas Pharma Corp. 26
Dong-A Socio Group 27
MedImmune, LLC 28
Meiji Seika Pharma Co., Ltd. 29
Melinta Therapeutics, Inc 30
Merck & Co., Inc. 31
Motif Bio Plc 32
Nabriva Therapeutics AG 33
Savara Inc. 34
Serendex Pharmaceuticals A/S 35
Tetraphase Pharmaceuticals Inc. 36
Hospital Acquired Pneumonia (HAP) - Therapeutics Assessment 37
Assessment by Monotherapy Products 37
Assessment by Combination Products 38
Assessment by Target 39
Assessment by Mechanism of Action 41
Assessment by Route of Administration 43
Assessment by Molecule Type 45
Drug Profiles 47
(amikacin + fosfomycin) - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
(ceftazidime + avibactam sodium) - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
(ceftolozane sulfate + tazobactam sodium) - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
AA-139 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
arbekacin - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
delafloxacin - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
eravacycline - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
iclaprim mesylate - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
lefamulin - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MEDI-3902 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
MEDI-4893 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
molgramostim - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
Nu-2 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Panaecin - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
plazomicin sulfate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pseudomonas + VAP vaccine - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
Pseudomonas aeruginosa vaccine - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Qn-2251 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
relebactam - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
tedizolid phosphate - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
tosatoxumab - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
vancomycin hydrochloride - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Hospital Acquired Pneumonia (HAP) - Recent Pipeline Updates 85
Hospital Acquired Pneumonia (HAP) - Dormant Projects 111
Hospital Acquired Pneumonia (HAP) - Discontinued Products 112
Hospital Acquired Pneumonia (HAP) - Product Development Milestones 113
Featured News & Press Releases 113
Jan 08, 2015: Achaogen Announces Plazomicin Granted QIDP Designation by FDA 113
Oct 03, 2013: Tetraphase to Present New Data at IDWeek on Eravacycline’s Potential Activity in Treating Serious Respiratory Infections 113
Sep 06, 2013: Trius Therapeutics to Present Data From Antibiotics Development Programs at ICAAC 2013 114
May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 115
May 07, 2013: Cubist’s Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 116
Jan 07, 2013: Trius Therapeutics's Tedizolid Receives Qualified Infectious Disease Product Designation From FDA 116
Dec 06, 2012: Cubist Pharma's Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA 117
Appendix 118
Methodology 118
Coverage 118
Secondary Research 118
Primary Research 118
Expert Panel Validation 118
Contact Us 118
Disclaimer 119

List of Tables
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2015 10
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 13
Number of Products under Investigation by Universities/Institutes, H2 2015 14
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Development, H2 2015 17
Comparative Analysis by Unknown Stage Development, H2 2015 18
Products under Development by Companies, H2 2015 19
Products under Development by Companies, H2 2015 (Contd..1) 20
Products under Investigation by Universities/Institutes, H2 2015 21
Hospital Acquired Pneumonia (HAP) - Pipeline by Achaogen Inc., H2 2015 22
Hospital Acquired Pneumonia (HAP) - Pipeline by Adenium Biotech ApS, H2 2015 23
Hospital Acquired Pneumonia (HAP) - Pipeline by Aridis Pharmaceuticals LLC, H2 2015 24
Hospital Acquired Pneumonia (HAP) - Pipeline by AstraZeneca Plc, H2 2015 25
Hospital Acquired Pneumonia (HAP) - Pipeline by Cardeas Pharma Corp., H2 2015 26
Hospital Acquired Pneumonia (HAP) - Pipeline by Dong-A Socio Group, H2 2015 27
Hospital Acquired Pneumonia (HAP) - Pipeline by MedImmune, LLC, H2 2015 28
Hospital Acquired Pneumonia (HAP) - Pipeline by Meiji Seika Pharma Co., Ltd., H2 2015 29
Hospital Acquired Pneumonia (HAP) - Pipeline by Melinta Therapeutics, Inc, H2 2015 30
Hospital Acquired Pneumonia (HAP) - Pipeline by Merck & Co., Inc., H2 2015 31
Hospital Acquired Pneumonia (HAP) - Pipeline by Motif Bio Plc, H2 2015 32
Hospital Acquired Pneumonia (HAP) - Pipeline by Nabriva Therapeutics AG, H2 2015 33
Hospital Acquired Pneumonia (HAP) - Pipeline by Savara Inc., H2 2015 34
Hospital Acquired Pneumonia (HAP) - Pipeline by Serendex Pharmaceuticals A/S, H2 2015 35
Hospital Acquired Pneumonia (HAP) - Pipeline by Tetraphase Pharmaceuticals Inc., H2 2015 36
Assessment by Monotherapy Products, H2 2015 37
Assessment by Combination Products, H2 2015 38
Number of Products by Stage and Target, H2 2015 40
Number of Products by Stage and Mechanism of Action, H2 2015 42
Number of Products by Stage and Route of Administration, H2 2015 44
Number of Products by Stage and Molecule Type, H2 2015 46
Hospital Acquired Pneumonia (HAP) Therapeutics - Recent Pipeline Updates, H2 2015 85
Hospital Acquired Pneumonia (HAP) - Dormant Projects, H2 2015 111
Hospital Acquired Pneumonia (HAP) - Discontinued Products, H2 2015 112

List of Figures
Number of Products under Development for Hospital Acquired Pneumonia (HAP), H2 2015 10
Number of Products under Development for Hospital Acquired Pneumonia (HAP) - Comparative Analysis, H2 2015 11
Number of Products under Development by Companies, H2 2015 12
Comparative Analysis by Late Stage Development, H2 2015 15
Comparative Analysis by Clinical Stage Development, H2 2015 16
Comparative Analysis by Early Stage Products, H2 2015 17
Assessment by Monotherapy Products, H2 2015 37
Assessment by Combination Products, H2 2015 38
Number of Products by Top 10 Targets, H2 2015 39
Number of Products by Stage and Top 10 Targets, H2 2015 39
Number of Products by Top 10 Mechanism of Actions, H2 2015 41
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 41
Number of Products by Top 10 Routes of Administration, H2 2015 43
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 43
Number of Products by Top 10 Molecule Types, H2 2015 45
Number of Products by Stage and Top 10 Molecule Types, H2 2015 45

Inquiry For Buying

Please fill your details below, to inquire about this report:
Indicates required fields

Request Sample

Please fill your details below, to receive sample report:
Indicates required fields

  • Payment Mode

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

Single User | $(USD)2000 View Pricing